Norwegian vaccine can stabilize cancer

A Norwegian vaccine under development by researchers at Oslo's Radium Hospital show clear signs of arresting and stabilizing the spread of cancer. They stress that this is no miracle cure. The team, headed by Professor Gustav Gaudernack, presented their findings Wednesday during the international cancer congress in Oslo. "It stabilizes only cancer cells. It does not cure, and it cannot prevent, cancer," Gauderneck said. The vaccine pinpoints the enzyme telomerase which gives cancer cells a kind of immortality by causing them to replicate indefinitely. The vaccine helps the immune system discover telomerase and destroy cancer cells before they have the opportunity to spread further. The vaccine has been tested on 32 patients with terminal cancer of the pancreas, many of whom were expected to live a maximum of 3-4 months. In some cases daily dosage of the vaccine extended the patient's life span to a year. Although statistical information is insufficient to draw any conclusions there are strong indications that higher dosages of the vaccine was linked to longer survival of terminal cancer.